Overview

A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Study in two stages, and with a sub-study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ARCAGY/ GINECO GROUP
Treatments:
Lenalidomide
Thalidomide